Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
First Claim
Patent Images
1. A detection reagent selected firm the group consisting of:
- (a) a detection reagent comprising at least about 15 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 15 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
G’
;
(b) a detection reagent comprising at least about 15 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 15 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
T’
; and
(c) a detection reagent which is entirely complementary to the detection reagent of (a) or (b).
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention is based on the discovery of novel polymorphisms (SNPs) in the genes known in the art to contribute to inflammatory and autoimmune disorders. Such polymorphisms can lead to a variety of disorders that are mediated/modulated by a variant inflammatory and autoimmune disorders associated protein. The present invention provides reagents used for detecting and expressing the variant nucleic acid/protein sequence as well as methods of identifying and using these variants.
-
Citations
20 Claims
-
1. A detection reagent selected firm the group consisting of:
-
(a) a detection reagent comprising at least about 15 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 15 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
G’
;
(b) a detection reagent comprising at least about 15 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 15 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
T’
; and
(c) a detection reagent which is entirely complementary to the detection reagent of (a) or (b). - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20)
-
-
2. An isolated polynucleotide selected from the group consisting of:
-
(a) an isolated polynucleotide consisting of a segment of SEQ ID NO;
1574, wherein the segment comprises at least about 12 contiguous nucleotides of SEQ ID NO;
1574, and wherein the at least about 12 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
G’
,(b) an isolated polynucleotide consisting of a sent of SEQ ID NO;
1574, wherein the segment comprises at least about 12 contiguous nucleotides of SEQ ID NO;
1574, and wherein the at least about 12 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
T’
; and
(c) an isolated polynucleotide which is entirely complementary to the isolated polynucleotide of (a) or (b).
-
-
3. A detection reagent selected from the group consisting of:
-
(a) a detection reagent comprising at least about 20 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 20 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
G’
;
(b) a detection reagent comprising at least about 20 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 20 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
T’
; and
(c) a detection reagent which is entirely complementary to the detection reagent of (a) or (b).
-
-
4. An isolated polynucleotide consisting of a nucleotide sequence selected from the group consisting of:
-
(a) the nucleotide sequence of SEQ ID NO;
1574, wherein position 301 of SEQ ID NO;
1574 is ‘
G’
;
(b) the nucleotide sequence of SEQ ID NO;
1574, wherein position 301 of SEQ ID NO;
1574 is ‘
T’
; and
(c) a nucleotide sequence which is entirely complementary to the nucleotide sequence of (a) or (b).
-
-
5. An isolated polynucleotide consisting of a segment of a nucleotide sequence selected from the group consisting of SEQ ID NOS:
- 602 and 764, wherein the segment comprises a nucleotide sequence selected from the group consisting of;
(a) the nucleotide sequence of SEQ ID NO;
1574, wherein position 301 of SEQ ID NO;
1574 is ‘
G’
;
(b) the nucleotide sequence of SEQ ID NO;
1574, wherein position 301 of SEQ ID NO;
1574 is ‘
T’
; and
(c) a nucleotide sequence which is entirely complementary to (a) or (b).
- 602 and 764, wherein the segment comprises a nucleotide sequence selected from the group consisting of;
-
6. An amplified polynucleotide selected from the group consisting of:
-
(a) an amplified polynucleotide comprising at least about 30 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 30 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
G’
;
(b) an amplified polynucleotide comprising at least about 30 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 30 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
T’
; and
(c) an amplified polynucleotide which is entirely complementary to the amplified polynucleotide of (a) or (b). - View Dependent Claims (11, 12)
-
-
7. An extension primer selected from the group consisting of:
-
(a) an extension primer comprising at least about 12 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 12 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
G’
, and wherein position 301 of SEQ ID NO;
1574 is a ddNTP at the 3′
end of the extension prier, and(b) an extension primer which is entirely complementary to the extension primer of (a).
-
-
8. An extension primer selected from the group consisting of:
-
(a) an extension primer comprising at least about 20 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 20 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
G’
, and wherein position 301 of SEQ ID NO;
1574 is a ddNTP at the 3′
end of the extension primer; and
(b) an extension primer which is entirely complementary to the extension primer of (a).
-
-
9. An extension primer selected from the group consisting of:
-
(a) an extension primer comprising at least about 12 contiguous nucleotides of SEQ ID NO;
1574, wherein the at least about 12 contiguous nucleotides include position 301 of SEQ ID NO;
1574, and wherein position 301 of SEQ ID NO;
1574 is ‘
T’
, and wherein position 301 of SEQ ID NO;
1574 is a ddNTP at the 3′
end of the extension primer, and(b) an extension primer which is entirely complementary to the extension primer of (a).
-
-
10. An extension primer selected from the group consisting of:
-
(a) an extension primer comprising at least about 20 contiguous nucleotides of SEQ ID NO;
1574, wherein the at let about 20 contiguous nucleotides include position 301 of SEQ ID NO;
574, and wherein position 301 of SEQ ID NO;
1574 is ‘
T’
, and wherein position 301 of SEQ ID NO;
1574 is a ddNTP at the 3′
end of the extension primer; and
(b) an extension primer which is entirely complementary to the extension primer of (a).
-
Specification